Novartis antibiotic retreat doesn’t stop Sandoz buying GSK d...

Novartis exited novel antibiotics R&D three years ago, but is clearly still interested in the category – its Sandoz unit has just spent $350 million buying GlaxoSmithKline’s cephalospor

1 week to SMi’s Superbugs & Superdrugs - REMOTE ACCESS ONLY

1 week to Superbugs & Superdrugs - REMOTE ACCESS ONLY

Interview with Martin Everett speaker at SMi’s Superbugs & S...

Interview with Martin Everett speaker at Superbugs

Still too little progress on antibiotic resistance, says O’N...

FDA okays Nabriva’s novel antibiotic Xenleta for pneumonia